Dr. Kelly has been involved in several clinical trials involving antipsychotic treatment for schizophrenia and has been active in psychopharmacology research for the past 12 years. She is also an investigator for many studies focusing on tolerability and clinical outcomes of people treated with antipsychotic medications. Some of her interests include sexual functioning and prolactin side effects, metabolic side effects and treatment, drug-interactions, suicide and mortality and dual diagnosis recognition and treatment. She has received research funding from the National Institutes of Mental Health to study long-term outcomes and mortality associated with antipsychotics, cardiovascular risk and substance abuse. Additionally she has received funding from the Stanley foundation, the pharmaceutical industry and from the National Institute for Drug Abuse. Dr. Kelly is currently the Principal Investigator on a 5-10 year contract with the National Institutes for Drug Abuse to study dually diagnosed patients.
Dr. Kelly has coauthored and authored 12 books and book chapters, published 65 peer-reviewed articles, presented over 90 posters and has given over 80 invited lectures. She has coauthored three editions of the book entitled "Pharmacologic Treatment of Schizophrenia." She also authors the Schizophrenia chapter for "Pharmacotherapy, Principles and Practice." Additionally, she has received the National Institute of Mental Health New Investigator Award and the International Congress on Schizophrenia Research Young Investigator Award. She was recently appointed as the Associate Editor for Clinical Schizophrenia and Related Psychoses. She also serves as Guest Editor for Schizophrenia Bulletin and has reviewed for over 30 psychiatry journals including Archives of General Psychiatry, American Journal of Psychiatry, Journal of Clinical Psychiatry, Schizophrenia Research and Psychiatric Services. She is also currently a member of the Department of VA Mental Health and Behavioral Sciences Review Committee for grant funding and serves on the State of Maryland Department of Health and Mental Hygiene Institutional Review Board.
Books and Book Chapters
Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. First Edition, Caddo, OK, 2000.
Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. Second Edition, Caddo, OK, 2003.
Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. Third Edition, Caddo, OK, 2007.
Conley RR, Kelly DL. The long-term efficacy, effectiveness and safety of second-generation antipsychotic drugs. In: Atypical antipsychotics: from bench to bedside. Editors: Csernansky JG, Lauriello J. Marcel Dekker, 2004.
Conley RR, Kelly DL. Schizophrenia. In: Conn's Current Therapy, 2005. Editors: Rakel R and Bope E. Philadelphia, PA: W.B. Saunders, Philadelphia 2005, pp. 1280-1284.
Conley RR, Kelly DL. Schizophrenia. In Conn's Current Therapy, 2006. Editors: Rakel R and Bope E. Philadelphia, PA: W. B. Saunders, Philadelphia, 2006, pp.1370-1374.
Boggs D, Kelly DL, Conley RR. Antipsychotic Therapeutics (Efficacy and Side Effects). In: The Year in Schizophrenia Volume I. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK. 2007,209-231.
Kelly DL, Weiner E. Schizophrenia. In: Pharmacotherapy Principles and Practice, Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2007.
Kelly DL, Boggs DL, Conley RR. Reaching for Wellness. In: Schizophrenia: A Complex Disease Necessitating Complex Care. Psychiatric Clinics of North America, Buckley PF, Messias EL (eds), Saunders, Philadelphia, PA , 2007; 30:453-479.
Boggs D, Kelly DL. Antipsychotic Therapeutics. In: The Year in Schizophrenia Volume II. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK. 2008
Kelly DL, Buchanan RW. Clozapine: Its Current Status in and Beyond Treatment Resistant Schizophrenia. In: Therapeutic Strategies in Schizophrenia. Eds., P McKenna, A. Mortimer. Clinical Publishing Limited. In press.
Wehring HJ, Kelly DL. Sexual Dysfunction in Schizophrenia. In: Medical Illness in Schizophrenia. In press.
Kelly DL, Weiner E, Wehring H. Schizophrenia. In: Pharmacotherapy Principles and Practice, Second edition. Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2009, in press
Kelly DL, Linthicum J, Wehring HJ, Feldman S, McMahon RP, Lover RC, Wagner T, Shim J-C, Fowler DR. Cardiac-Related Autopsy Findings in People with Severe Mental Illness Treated with Clozapine or Risperidone. Schizophrenia Research 2009;107:134-8
Conley RR, Boggs DL, Kelly DL, McMahon RP, Feldman S, Ball P, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clinical Neuropharmacology, 2008; epub ahead of print.
Kelly, DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic Risk With Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry, 2008;20:71-8
Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in Schizophrenia: The Relationship to Baseline Symptoms and Changes in Symptom Domains During a One-Year Study. J of Psychopharmacology, 2008, epub ahead of print.
Kelly DL, Weiner E, Conley RR, McMahon RP, Buchanan RW. Lack of Beneficial Galantamine Effect for Smoking Behavior: A Double-Blind Randomized Trial in People with Schizophrenia. Schizophrenia Research, 2008;103;161-8.
Shim JC, Liu Y-S, Kelly DL. Aripiprazole Treatment Causes Extrapyramidal Side Effects but Not Prolactin Elevations: A Disconnect of the Striatal D2 Occupancy Story. J Clin Psychopharmacology, 2008;28(3):353-354.
Boggs DL, Kelly DL, Nelson MW, Yu Y, Feldman S, McMahon RP, Conley RR. Quetipine at High doses for Treatment. Refractory Schizophrenia. 2008;101:347-8.
McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT. Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. Schizophrenia Bull, 2008;34:298-301.
Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. Psychiatric Quarterly, 2008;79(2):111-119.
Shim J-C, Shin J-G, Kelly DL, Jung D-U, Seo Y-S, Liu KH, Sohn J-H, Conley RR. Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. American Journal of Psychiatry, 2007;164:1004-10.
Conley RR, Kelly DL. Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2007;3:135-146.
Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK, Kelly DL, Conley RR. Discontinuation of Risperidone, Olanzapine, and Haloperidol in First Episode Psychosis. J Clin Psychopharmacol, 2007;27:400-401.
Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra MK. Why Not Clozapine? Clinical Schizophrenia & Related Psychoses, 2007;1:92-5.
Conley RR, Kelly DL. Drug: drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients. Psychopharmacology Bulletin, 2007;40:77-97.
Kelly DL. Treatment Considerations in Women with Schizophrenia. Journal of Women's Health, 2006;15:1132-40.
Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine Underutilization and Discontinuation in African-Americans Due to Leucopenia. Schizophrenia Bulletin, 2007;33:1221-4.
Kelly DL, Dixon L, Kreyenbuhl J, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. J Clin Psychiatry, 2006;67:1404-11
Jung D-O, Conley RR, Kelly DL, Kim D_W, Yoon S-H, Jang J-H, Shin J-G, Shim J-C. The Prevalence of Bone Mineral Density Loss in the Korean Patients with Chronic Schizophrenia. J Clin Psychiatry, 2006;67:1391-96.
Kelly DL, Richardson CM, Yu Yang, Conley RR. Plasma Concentrations of High Dose Olanzapine in a Double Blind Crossover Study. Human Psychopharmacology: Clinical and Experimental, 2006;21:393-8.
Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatric Quarterly, 2006;77(1):81-95.
Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology, 2006;31;340-346.
Conley RR, Shim JC, Kelly DL, Yu Y, Feldman S, McMahon RP. Cardiovascular disease in Relation to Weight in deceased persons with schizophrenia. Comprehensive Psychiatry, 2005;46:460-7.
Conley RR, Kelly DL. Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment. Medicinal Chemistry Reviews - Online. 2005;2(3):177-182.
Jung DU, Seo YS, Park JH, Jeong CY, Conley RR, Kelly DL, Shim JC. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005;25:13-15.
Kelly DL. The Schizophrenic Patient: The Reproductive Years and Beyond The Female Patient, OB-GYN edition, 2005;30(8):22-31.
Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Israel Journal of Psychiatr and Related Sciences, 2005;42(1):51-60.
Conley RR, Kelly DL, Nelson M, Richardson CM, Feldman S, Reynolds R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love R. Risperidone and quetiapine vs. fluphenazine in treatment-resistant schizophrenia. Clinical Neuropharmacology, 2005;28(4):163-8.
Kelly DL, Carpenter WT, Conley RR. First Episode Schizophrenia: A Focus on Pharmacologic Treatment and Safety Considerations. Drugs, 2005;65:1113-38.
Conley RR, Kelly DL, Lambert TJ, Love RC. A comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services 2005;56:320-3.
Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine. Journal of Clinical Psychiatry, 2005;66:80-84.
Shim J-C Kim Y-H, Kelly DL, Lee J-G, Conley RR. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2005;17:221-6.
Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophrenia Bulletin, 2004;30:767-779.
Kelly DL, Shim J-C, Feldman SM, Yu Y, Conley RR. Lifetime Psychiatric Symptoms in Persons with Schizophrenia Who Died by Suicide Compared to Other Means of Death. J of Psychiatric Research, 2004;38:531-36.
Kelly DL, Love RC, Mackowick M, Conley RR. Atypical Antipsychotic Use in a State Hospital Inpatient Adolescent Population, Journal of Child and Adolesc Psychopharmacology, 2004; 14(1):75-85.
Conley RR, Kelly DL, Beason-Held, Holcomb H, Richardson C, Tamminga CA, Carpenter WT. The effects of clozapine and high dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology, 2004;18:429-31.
Kim YH, Shim J-C, Kelly DL, Lee J-G, Seo Y-S, Conley RR. Cortisol Response to Buspirone in Extended Abstinent Alcoholics. Alcohol and Alcoholism, 2004;39(4):287-289.
Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. Annals of Clin Psychiatry, 2003;15:181-6.
Kelly DL, Kreyenbuhl J, Love RC, Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. Journal of Clinical Psychiatry, 2003;64:1133-4
Kelly DL, Gale EA, Yu Y, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry 2003;48(2):111-4.
Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophrenia Research 2003;63:195-196.
Lambert, TJ, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacology, 2004;24:91-3.
Wehring H, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry, 2003;160:2241-2242.
Lambert TJR, Cock N, Alcock S, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) vs. structured interview (UKU) approach to measurement. Human Psychopharmacology 2003;18(5): 405-41.
Nelson M, Conley RR, Reynolds R, Kelly DL. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone: case report. Clinical Neuropharmacology, 2003;26:297-8.
Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry, 2003;15:23-31.
Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The Efficacy of High Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study. J Clin Psychopharmacology, 2003;23:668-671.
Lambert TJ, Brenan A, Castle DJ, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatric Practice, 2003;9(3):252-260.
Love RC, Kelly DL. Olanzapine and risperidone. American Journal of Health-Systems Pharmacy, 2003;60:487-88.
Shim J-C, Kelly DL, Kim Y-H, Yoon Y-R, Park JH, Shin J-G, Conley RR. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacology, 2003;520-2.
Conley RR, Kelly DL. Current status of antipsychotic treatment. Current Drug Targets - CNS and Neurological Disorders 2002;1:123-128.
Kreyenbuhl J, Kelly DL, Conley RR. Circumstances of suicide among patients with schizophrenia. Schizophrenia Research, 2002;58 (2-3):253-61.
McMahon RP, Kelly DL Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment-resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology, 2002; 537-545
Kelly DL, Love RC. Ziprasidone and the QTc: pharmacokinetic and pharmacodynamic considerations. Psychopharmacology Bulletin 2001;35:66-79.
Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating associated with clozapine use. Am J Psychiatry 2001;158:1329-30.
Conley RC, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry 2001;50:898-911.
Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatric Services 2001;52:676-8.
Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophrenia Research, 1999; 40(2): 101-4.
Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics. The Journal of the Child and Adolescent Psychopharmacology, 1998;8:151-159.
Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry 1999;156:863-868.
Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 1999;46;73-77.
Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry, 1999;60:771-775.
Sherr JD, Kelly DL. Substitution of immediate release valproic acid for divalproex sodium for adult psychiatric inpatients. Psychiatric Services 1998;49:1355-57.
Conley, RR, Kelly DL, Gale E. Olanzapine response in therapy-refractory schizophrenia with substance abuse. Schizophrenia Research 1998;33:95-101.
Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates of depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. American Journal of Health-Systems Pharmacy 1998; 55(4):17-19.
Peer-Reviewed Articles In Press, Under Review, or In Development
Kelly DL, McMahon RP, Liu Fang, Love RC, Wehring H, Shim JS, Wagner T, Yu Y, Conley RR. Cardiac-related mortality in chronic schizophrenia patients treated with clozapine. J Clin Psychiatry, in press.
Kelly DL, Feldman S, Boggs DL, Gale E, Richardson CM, Conley RR. Premorbid Functioning and Clozapine Response in Treatment Refractory Schizophrenia. Comprehensive Psychiatry, under review
Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Nelson M, Dickinson D, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. Atomoxetine for Neurocognitive Deficits in People with Schizophrenia. J Clinical Psychiatry, in press.
McMahon RP, Kelly DL, Conley RR. An Outcome Ranking for Intention to Treat Effectiveness Analysis in Schizophrenia Trials. In development
Love RC, Kelly DL, Boggs DL. Risperidone versus olanzapine in the treatment of schizophrenia: a review of studies comparing cost and utilization. In development.
Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, McEvoy JP, Fassano A, Eaton WW. Prevalence of celiac disease and gluten sensitivity in the CATIE study population: evidence for a link between schizophrenia and gluten reactivity. Schizophrenia Bulletin, under review
Warren KR, Kelly DL. Brief Psychotic Disorders. British Journal of Psychiatry Monograph, under review
Shim J-C, Jung D-U, Oh M-K, Kong B-G, Kelly DL. Bone Mineral Density and Osteoporosis Risk in Older Men and Women with Schizophrenia: A 3-4 year follow-up study, in development.